-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $37

Benzinga·11/13/2026 17:48:39
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $37.